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(1400 DNA copies/mL), prompting foscarnet initiation. Her MS 
greatly improved after the first week of antiviral therapy. Serum 
HHV-6 PeR became negative and a LP on D+53 revealed a nor- 
mal protein and CSF PCR for HHV-6 had decreased to 110 DNA 
copies/mL. She was changed to maintenance valganciclovir and 
TPE was tapered and discontinued after remittance of her TMA 
and normalization of her MS. hnportantly, HHV-6 reactivation 
must be considered in adult patients undergoing ASCT who 
develop encephalopathy, fevers of unknown origin, rash, or TMA. 
An aggressive pursuit of this diagnosis in the appropriate clinical 
setting is critical given its often fuhninant course in immnnosup- 
pressed patients who are left untreated. 
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MULTIPLE 
MYELOMA (MM): ACHIEVEMENT OF CR IS ASSOCIATED WITH 
IMPROVED SURVIVAL 
Kmnar, L/; Kochupillai, ~U; Ga77essan, K~ 1. ALL India bzstitute of
k/ledical ScieJlces, Neu, Delhi, Delhi, II~dia; 2. All flzdia ITzstitztte of 
Medical Sciences, Nezz, Delhi, Delhi, India; 3. All India b~stitute of 
k/leclical Sciences, New Delhi, Delhi, imtia. 
Background : HD-CT  with ASCT is currently used in the treat- 
meat (Tt) of patients (Pts) with advanced MM.  Methods : 50 Pts 
(median age-52 years, range, 26-65) with advanced MM under- 
went T t  with HD melphalan with ASCT (BM -7, PB -43). M:F : 
35:15. All Pts initially had received CT, mean no of CT  cycles 
9.38 (range, I- 36). 30/50 (60%) patients had evidence of chemo- 
sensitive disease at transplant (Tx). Mean interval from diagnosis 
to Tx was 17.5 months (range, 3 to 129). Median no of MNC 
infused was 4. 86 xl0(8)/kg (range, 2 - 10.48). Results : Post -Tx, 
43 / 50 Pts engrafted; median no of days to engraft  (ANC 
(>g00/cmm) was 12 days (range, 9 - 24) & to achieve platelet 
transfusion independence (>20 K) was 13 days (range, 8 - 36). 
Grade III-IV oral mucositis was major non-haematologic toxicity. 
Following Tx, 78% of Pts responded; CR - 29 (58)%, & PR - 
20%. CR rate was higher for Pts with chemo-sensitive dis. ; 20/26 
Pts with PR at Tx achieved CR vs 5/20 Pts with persistentJrefrac- 
to W dis., p<.01. Post Tx, Pts received interferon-alfa (3 mU 3/wl 0 
for one year. Currently, 34/43 Pts (79%) are alive, 17 (39.5%) dis- 
ease-free, 9(21%) Pts have died ; 8 of progressive dis. & 1 of unre- 
lated cause. The  median FU for the whole group is 26 mon. 
(range, 1-144 nmnths). Estimated OS & PFS at 55 months is 58% 
& 34%, respectively. Low Hb (<10g%) (p<.003) & stage B dis. at 
diagnosis affected the survival adversely. Chemo-sensi t ive 
dis.(p<.008) at Tx and achievement of CR post - Tx (<.0001) were 
associated with significantly ilnproved sm-vival. Conclusions: HD 
melphalan with ASCT is an effective Tt  for advanced myeloma .
Achievement of CR is associated with improved survival. 
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REQUIRING MORE THAN TWO APHERESIS PROCEDURES IMPACTS 
ADVERSELY ON OUTCOME OF AUTOLOGOUS PERIPHERAL BLOOD 
STEM CELL TRANSPLANTATION 
Nieder, M.L.; k/lcCrae, E.; Fisher, V.L.; Fox, R.; Creger, R.; Lazavas, 
H.M., O'RioJ'&m, M. Case HZeste'rn Reserve University, Clevelamt, OH. 
Despite improvements in transplantation co-incident with the 
switch from marrow to blood, there remain obstacles to success 
(early relapse, failure to mobilize stenr cells). We reviewed our 
extensive 4 year experience to identify predictive factors for suc- 
cessful engraftment and survival. We wanted to determine if cer- 
tain difficulties encountered uring PBSC acquisition via aphere- 
sis had any affect on eventual engraftment after transplantation. 
We performed 790 apheresis procedures on 274 patients from 
1998-2001 (age range 7 months-69 years). The  majority of 
patients were mobilized with chenmtherapy and GCSF. However, 
a small number of patients received a combination of GM-CSF 
and G-CSF prior to PBSC collection. Of the entire group, 231 
patients (85%) eventually underwent transplantation. 7.3% of the 
patients were not transplanted because of unsuccessful mobiliza- 
tion/steln cell collection. Patients most conmmnly underwent 
transplantation as therapy for leukemia, breast cancer, Hodgldns 
and NonHodgkins Lymphoma and multiple myeloma. Patients 
who needed to undergo only 1 or 2 apheresis procedures (as com- 
pared to those needing 3 or more) had earlier engraftment of 
WBC and platelet counts and fewer infectious complications. 
These data suggest that patients who require more than two 
apheresis procedures prior to autograft should be considered at 
increased risk for complications during transplantation. Perhaps 
information regarding this increased risk should be incorporated 
into patient pre-transplant discussions and consent. 
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ENGRAFTMENT SYNDROME IN AUTOLOGOUS TRANSPLANTATION: A 
FUNCTION OF CD34+ CELL DOSE 
Dmlato, ~I.L.; Saliba, R.k/l.; Aleman, A.; Ippol#i, C.; Gershemon, D.; 
Betha,icow-t, D.; CTaampli,z, R. The University ofTexas k/I.D. Amler- 
solz Cancer Cente*', Hoaston, 7P~(. 
Engraftment syndrome (ES) has been described in the autologous 
transplant setting. Our aim was to determine factors predictive of 
ES in a uniform population. We have analysed 101 patients with 
advanced ovarian cancer receiving high-dose topotecan, melphalan 
and cyclophosphamide with autologous tem cell transplantation. 
Engraftment fever (EF) was the only component of ES observed in 
this group and was defined as onset of ever > 38 ° C within 3 days 
pre and 4 days post engrafnnent. Patients with fever starting prior to 
that or associated with an infection were considered unevaluable (18 
patients). The median age was 50 y (21-67y). The median time to 
ARC >0.5x109 was 9 days (8-11) and to platelets > 100xl09 was 15 
days (10-322). There were no transplant-related deaths. Of  the 83 
evaluable patients 37 (45%) had engraftment fever (38 ° - 39 ° C). 
These patients had received asignificantly higher number of CD34+ 
cells/kg (median 7.7 vs 10.1) p=0.01. Twenty patients (54%) with 
engraftment fever had peripheral blood blasts in the engraftment 
period compared to 13 % for patients without fever p<0.001.54% of 
patients with engraftment fever received methylprednisolone 
emperically, mostly lmg/kg (range 0.5-6.5 mg/kg). Age, prior ther- 
apy, and regimen-related to,city were not associated with a higher 
incidence of EF. The presence of EF had no impact on survival or 
progression-free survival. In conclusion, patients receiving >8- 
10xl 06 CD34+ cells/kg are at increased risk of developing engraft- 
ment fever and ma W will present with circulating blasts on engraft- 
nrent. Whether steroids are advisable remains to be determined. 
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THE EFFECT OF GLUTAMINE ON DISEASE PROGRESSION IN MULTIPLE 
MYELOMA (MM) PATIENTS RECEIVING HIGH-DOSE MELPHALAN 
Crook, if.L; H~lsale1~ko, if.I(.; Myhamt, R.C. H~dter Reed Alvny3/led- 
k'al Ce~ter, lT/ashiJ~gto~z, DC. 
Mucositis, a frequent complication of high-dose therapy, is asso- 
ciated with major morbidity and mortality. Glutamine is one 
agent hat has been shown to protect he gastro-intestinal epitheli- 
um from the toxic effects of chenmtherapy. Although oral gluta- 
mine has been used successfully to prevent transplant related 
mucositis, the potential for glutamine mediated tunmr protection 
has not been systematically investigated. In order to identify any 
possible tumor protective ffect of glutamine in high-dose thera- 
py, we performed a retrospective review of consecutive patients 
who received high-dose therapy with melphalan (200 rag/m2) for 
MM either with or without glutamine. Between July 1997 and 
August 2002, 41 patients were treated at our institution. The first 
17 patients did not receive glutamine prophylaxis. In July 2000, we 
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